Top 5 Health-Care Tweets of the Week

Twitter is without a doubt the most useful tool for gathering information about the health-care sector; but only if you follow the right people, and read everything they tweet. Even then there's a lot of noise that you have to filter through.

In this new weekly column, I'll try to help you out, bringing you the top tweets I see, with some commentary. Read to the end to see how you can help make it even better.

Phil identifies the major problem with shorting smaller biotechs and medical-device makers. There's no telling when a large player is going to come along and purchase the company for a hefty premium. This week, Stryker took out MAKO Surgical (UNKNOWN: MAKO.DL  ) for 85% higher than it closed the day before. All those shares sold short will have to be repurchased at the higher valuation.

Your short thesis about a small company struggling to sell its drug or device might be completely correct, but that doesn't mean a larger company won't think it can do better.

Biotech is volatile; but, unfortunately, reducing risk also limits results. Ross missed a 10% run trying to preserve capital.

Amarin (NASDAQ: AMRN  ) has been on a bit of a terror since early August as investors anticipate the Food and Drug Administration advisory committee meeting on October 16 to expand the use of Vascepa to patients with moderately high triglyceride levels. Investors love catalysts, so the run up isn't all that unexpected, but it may be a bumpy road to get there.

Vikram is referring to the cholesterol-lowering drugs that target PCSK9, a protein that binds to the LDL cholesterol receptor, and blocks its degradation. Blocking PCSK9 -- Amgen (NASDAQ: AMGN  ) and Regeneron Pharmaceuticals (NASDAQ: REGN  ) are doing it with antibodies, Alnylam Pharmaceuticals (NASDAQ: ALNY  ) is taking an RNAi approach -- results in LDL cholesterol receptor degradation and, therefore, less of the bad LDL cholesterol.

Amgen's AMG145, and Regneron's alirocumab, which is partnered with Sanofi, are in the lead with phase 3 programs in process, but there are plenty of other drugmakers going after the prize. In addition to the aforementioned Alnylam, Pfizer, Novartis, and Roche also have PCSK9 programs. Handicapping how much of the market each drug will get is going to be difficult, but that doesn't mean analysts won't try.

Agreed. Using "potent" to describe retaspimycin when reporting the failure of a clinical trial is bad form. Infinity Pharmaceuticals (NASDAQ: INFI  ) is now focused on IPI-145, which the biotech also describes as "potent." Hope that's not a sign.

Perhaps Infinity should wait until proof-of-concept trials are complete before ascribing adjectives to its compounds. What's potent in the lab isn't necessarily what's potent in the clinic.

In case you hadn't heard, the health exchanges open October 1. The article covers what 80% of Americans need to know. It's not what you think.

Your top tweets
See a tweet you think is worthy of a spot in the top five? You can tweet me a link to the tweet at @BiologyFool. Insights, investment lessons, and general Foolery are highly encouraged.

Game-changing biotechs
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2658683, ~/Articles/ArticleHandler.aspx, 7/28/2014 1:04:36 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement